Literature DB >> 24070153

Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond.

Stephen M Vindigni1, Elizabeth K Broussard, Christina M Surawicz.   

Abstract

Clostridium difficile infection is increasingly common with a high risk of recurrence despite antibiotic treatment. In cases of recurrent C. difficile infection, fecal microbiota transplant (FMT) is a highly effective treatment option promoting the restoration of normal gut microbiota. Furthermore, preliminary uncontrolled evidence demonstrates possible benefit of FMT in the management of some cases of inflammatory bowel disease and chronic constipation. In addition to presenting an overview of FMT, we discuss the role of probiotics, a more common approach to modifying the intestinal microbiome. Probiotics have been utilized broadly for many disease processes, including gastrointestinal, cardiovascular and allergic disease settings, although with limited and inconsistent results. Multiple potential areas for research are also identified.

Entities:  

Mesh:

Year:  2013        PMID: 24070153     DOI: 10.1586/17474124.2013.832501

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  9 in total

1.  Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?

Authors:  Sajiv Chandradas; Hamed Khalili; Ashwin Ananthakrishnan; Connor Wayman; Warren Reidel; Jill Waalen; Gauree G Konijeti
Journal:  Dig Dis Sci       Date:  2018-05-19       Impact factor: 3.199

2.  C. difficile Infection: Changing Epidemiology and Management Paradigms.

Authors:  Stephen M Vindigni; Christina M Surawicz
Journal:  Clin Transl Gastroenterol       Date:  2015-07-09       Impact factor: 4.488

3.  Fecal transplantation indications in ulcerative colitis. Preliminary study.

Authors:  Mihaela Laszlo; Lidia Ciobanu; Vasile Andreica; Oliviu Pascu
Journal:  Clujul Med       Date:  2016-04-15

4.  A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.

Authors:  Diane J Schmidt; Gillian Beamer; Jacqueline M Tremblay; Jennifer A Steele; Hyeun Bum Kim; Yaunkai Wang; Michele Debatis; Xingmin Sun; Elena A Kashentseva; Igor P Dmitriev; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

5.  Recent advances in the treatment of C. difficile using biotherapeutic agents.

Authors:  Vo Van Giau; Hyon Lee; Seong Soo A An; John Hulme
Journal:  Infect Drug Resist       Date:  2019-06-10       Impact factor: 4.003

6.  Potential role of gastrointestinal microbiota composition in prostate cancer risk.

Authors:  E Susan Amirian; Joseph F Petrosino; Nadim J Ajami; Yanhong Liu; Martha P Mims; Michael E Scheurer
Journal:  Infect Agent Cancer       Date:  2013-11-04       Impact factor: 2.965

Review 7.  Fecal microbiota transplantation: current clinical efficacy and future prospects.

Authors:  Kathryn A Bowman; Elizabeth K Broussard; Christina M Surawicz
Journal:  Clin Exp Gastroenterol       Date:  2015-10-23

Review 8.  The Mammalian Intestinal Microbiome: Composition, Interaction with the Immune System, Significance for Vaccine Efficacy, and Potential for Disease Therapy.

Authors:  Ulrich Desselberger
Journal:  Pathogens       Date:  2018-06-21

9.  Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis.

Authors:  Rei Kawashima; Shun Tamaki; Fumitaka Kawakami; Tatsunori Maekawa; Takafumi Ichikawa
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.